Drug and Therapeutics Bulletin 2002;40:62-64; doi:10.1136/dtb.2002.40862
Copyright © 2002 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Seretide and {blacktriangledown}Symbicort in asthma management

Relevant BNF section: 3.2

Maintenance treatment for mild asthma frequently comprises both a regular inhaled corticosteroid and an 'as required' inhaled short-acting ß2-agonist. Where such treatment fails, additional regular treatment with an inhaled long-acting ß2-agonist is increasingly recommended.1 In the UK, combination inhalers containing salmeterol + fluticasone ({blacktriangledown}Seretide - Allen & Hanburys) or formoterol + budesonide ({blacktriangledown}Symbicort - AstraZeneca) are licensed for use either in "patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting ß2-agonists" or in "patients already adequately controlled on both inhaled corticosteroids and long-acting -agonists".2–4 Here we review the efficacy of Seretide and Symbicort and discuss their place in asthma management.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2002 BMJ Publishing Group Ltd.